Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1

Interventions

Taxes 3Paclitaxel 3Carboplatin 3Immunoglobulin G 2Disulfides 2Bevacizumab 2sargramostim 1pegfilgrastim 1emactuzumab 1X-Rays 1Thiotepa 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Reverse Transcriptase Polymerase Chain Reaction 1Practice Guidelines as Topic 1Peripheral Blood Stem Cell Transplantation 1Metformin 1Mesenchymal Stem Cell Transplantation 1Melphalan 1Magnetic Resonance Spectroscopy 1Immunologic Techniques 1Granulocyte-Macrophage Colony-Stimulating Factor 1Filgrastim 1Exercise 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Cytoreduction Surgical Procedures 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Brenner Tumor × emactuzumab × Clear all
NCT02923739 2024-03-13

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
9 enrolled 9 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡